ADTX Stock Overview
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
Aditxt, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.17|
|52 Week High||US$3.95|
|52 Week Low||US$0.12|
|1 Month Change||-12.62%|
|3 Month Change||-41.40%|
|1 Year Change||-92.15%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-96.63%|
Recent News & Updates
Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Aditxt (NASDAQ:ADTX) said on Friday that it completed a toxicology study that indicated the safety of its immunotherapeutic technology drug ADI-100, to treat rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. (ADTX) stock surged 61% before the bell. The company said that the result will provide help when the company files an Investigational New Drug (IND) application with the regulatory agencies.
|ADTX||US Biotechs||US Market|
Return vs Industry: ADTX underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: ADTX underperformed the US Market which returned -11.6% over the past year.
|ADTX Average Weekly Movement||26.9%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ADTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 27% a week.
Volatility Over Time: ADTX's weekly volatility has increased from 21% to 27% over the past year.
About the Company
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.
Aditxt, Inc. Fundamentals Summary
|ADTX fundamental statistics|
Is ADTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADTX income statement (TTM)|
|Cost of Revenue||US$266.05k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.83|
|Net Profit Margin||-14,604.80%|
How did ADTX perform over the long term?See historical performance and comparison